Medtronic settles heart valve patent war with Edwards LifeSciences

Edwards Lifesciences and Medtronic announced a settlement relating to a patent dispute over transcatheter heart valve

Following years of being entrenched in an arduous legal war, Edwards Lifesciences and Medtronic announced a settlement relating to a patent dispute over transcatheter heart valve.

The replacement valve spares patients from open heart surgery. Reuters reports the market in the U.S. for the procedure is expected to top $500 million in 2014, and will likely double that by 2018. Edwards was first to market with its Sapien technology valve in 2011 in the U.S. while Medronic received regulatory approval for CoreValve earlier this year.

Contributing Author

author image

Alexis Harrison

Alexis Harrison is a Connecticut-based writer and public relations professional whose career spans both print journalism and broadcast news. Alexis started her professional life as...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.